Literature DB >> 23741013

Bone morphogenetic protein 9 (BMP9) controls lymphatic vessel maturation and valve formation.

Sandrine Levet1, Delphine Ciais, Galina Merdzhanova, Christine Mallet, Teresa A Zimmers, Se-Jin Lee, Fabrice P Navarro, Isabelle Texier, Jean-Jacques Feige, Sabine Bailly, Daniel Vittet.   

Abstract

Lymphatic vessels are critical for the maintenance of tissue fluid homeostasis and their dysfunction contributes to several human diseases. The activin receptor-like kinase 1 (ALK1) is a transforming growth factor-β family type 1 receptor that is expressed on both blood and lymphatic endothelial cells (LECs). Its high-affinity ligand, bone morphogenetic protein 9 (BMP9), has been shown to be critical for retinal angiogenesis. The aim of this work was to investigate whether BMP9 could play a role in lymphatic development. We found that Bmp9 deficiency in mice causes abnormal lymphatic development. Bmp9-knockout (KO) pups presented hyperplastic mesenteric collecting vessels that maintained LYVE-1 expression. In accordance with this result, we found that BMP9 inhibited LYVE-1 expression in LECs in an ALK1-dependent manner. Bmp9-KO pups also presented a significant reduction in the number and in the maturation of mesenteric lymphatic valves at embryonic day 18.5 and at postnatal days 0 and 4. Interestingly, the expression of several genes known to be involved in valve formation (Foxc2, Connexin37, EphrinB2, and Neuropilin1) was upregulated by BMP9 in LECS. Finally, we demonstrated that Bmp9-KO neonates and adult mice had decreased lymphatic draining efficiency. These data identify BMP9 as an important extracellular regulator in the maturation of the lymphatic vascular network affecting valve development and lymphatic vessel function.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23741013      PMCID: PMC3724195          DOI: 10.1182/blood-2012-12-472142

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  31 in total

1.  PDZ interaction site in ephrinB2 is required for the remodeling of lymphatic vasculature.

Authors:  Taija Mäkinen; Ralf H Adams; John Bailey; Qiang Lu; Andrew Ziemiecki; Kari Alitalo; Rüdiger Klein; George A Wilkinson
Journal:  Genes Dev       Date:  2005-02-01       Impact factor: 11.361

2.  Exploiting lymphatic transport and complement activation in nanoparticle vaccines.

Authors:  Sai T Reddy; André J van der Vlies; Eleonora Simeoni; Veronique Angeli; Gwendalyn J Randolph; Conlin P O'Neil; Leslie K Lee; Melody A Swartz; Jeffrey A Hubbell
Journal:  Nat Biotechnol       Date:  2007-09-16       Impact factor: 54.908

3.  Angiopoietin-1 promotes lymphatic sprouting and hyperplasia.

Authors:  Tuomas Tammela; Anne Saaristo; Marja Lohela; Tohru Morisada; Jenny Tornberg; Camilla Norrmén; Yuichi Oike; Katri Pajusola; Gavin Thurston; Toshio Suda; Seppo Yla-Herttuala; Kari Alitalo
Journal:  Blood       Date:  2005-03-03       Impact factor: 22.113

4.  Defective valves and abnormal mural cell recruitment underlie lymphatic vascular failure in lymphedema distichiasis.

Authors:  Tatiana V Petrova; Terhi Karpanen; Camilla Norrmén; Russell Mellor; Tomoki Tamakoshi; David Finegold; Robert Ferrell; Dontscho Kerjaschki; Peter Mortimer; Seppo Ylä-Herttuala; Naoyuki Miura; Kari Alitalo
Journal:  Nat Med       Date:  2004-08-22       Impact factor: 53.440

Review 5.  Emerging role of bone morphogenetic proteins in angiogenesis.

Authors:  Laurent David; Jean-Jacques Feige; Sabine Bailly
Journal:  Cytokine Growth Factor Rev       Date:  2009-06-06       Impact factor: 7.638

6.  Bone morphogenetic protein-9 is a circulating vascular quiescence factor.

Authors:  Laurent David; Christine Mallet; Michelle Keramidas; Noël Lamandé; Jean-Marie Gasc; Sophie Dupuis-Girod; Henri Plauchu; Jean-Jacques Feige; Sabine Bailly
Journal:  Circ Res       Date:  2008-02-28       Impact factor: 17.367

Review 7.  Diagnosis and management of lymphatic vascular disease.

Authors:  Stanley G Rockson
Journal:  J Am Coll Cardiol       Date:  2008-09-02       Impact factor: 24.094

8.  FOXC2 controls formation and maturation of lymphatic collecting vessels through cooperation with NFATc1.

Authors:  Camilla Norrmén; Konstantin I Ivanov; Jianpin Cheng; Nadine Zangger; Mauro Delorenzi; Muriel Jaquet; Naoyuki Miura; Pauli Puolakkainen; Valerie Horsley; Junhao Hu; Hellmut G Augustin; Seppo Ylä-Herttuala; Kari Alitalo; Tatiana V Petrova
Journal:  J Cell Biol       Date:  2009-04-27       Impact factor: 10.539

9.  Integrin-alpha9 is required for fibronectin matrix assembly during lymphatic valve morphogenesis.

Authors:  Eleni Bazigou; Sherry Xie; Chun Chen; Anne Weston; Naoyuki Miura; Lydia Sorokin; Ralf Adams; Andrés F Muro; Dean Sheppard; Taija Makinen
Journal:  Dev Cell       Date:  2009-08       Impact factor: 12.270

Review 10.  Flow control in our vessels: vascular valves make sure there is no way back.

Authors:  Eleni Bazigou; Taija Makinen
Journal:  Cell Mol Life Sci       Date:  2012-08-25       Impact factor: 9.261

View more
  55 in total

1.  BMP-9 balances endothelial cell fate.

Authors:  Rik Derynck; Rosemary J Akhurst
Journal:  Proc Natl Acad Sci U S A       Date:  2013-11-12       Impact factor: 11.205

Review 2.  A tale of two models: mouse and zebrafish as complementary models for lymphatic studies.

Authors:  Jun-Dae Kim; Suk-Won Jin
Journal:  Mol Cells       Date:  2014-05-23       Impact factor: 5.034

Review 3.  Diversity is in my veins: role of bone morphogenetic protein signaling during venous morphogenesis in zebrafish illustrates the heterogeneity within endothelial cells.

Authors:  Jun-Dae Kim; Heon-Woo Lee; Suk-Won Jin
Journal:  Arterioscler Thromb Vasc Biol       Date:  2014-07-24       Impact factor: 8.311

Review 4.  Development of the mammalian lymphatic vasculature.

Authors:  Ying Yang; Guillermo Oliver
Journal:  J Clin Invest       Date:  2014-03-03       Impact factor: 14.808

5.  Temporal and spatial regulation of epsin abundance and VEGFR3 signaling are required for lymphatic valve formation and function.

Authors:  Xiaolei Liu; Satish Pasula; Hoogeun Song; Kandice L Tessneer; Yunzhou Dong; Scott Hahn; Tadayuki Yago; Megan L Brophy; Baojun Chang; Xiaofeng Cai; Hao Wu; John McManus; Hirotake Ichise; Constantin Georgescu; Jonathan D Wren; Courtney Griffin; Lijun Xia; R Sathish Srinivasan; Hong Chen
Journal:  Sci Signal       Date:  2014-10-14       Impact factor: 8.192

Review 6.  Bone Morphogenetic Proteins.

Authors:  Takenobu Katagiri; Tetsuro Watabe
Journal:  Cold Spring Harb Perspect Biol       Date:  2016-06-01       Impact factor: 10.005

7.  Impact of selective anti-BMP9 treatment on tumor cells and tumor angiogenesis.

Authors: 
Journal:  Mol Oncol       Date:  2016-12       Impact factor: 6.603

Review 8.  ALK1 signaling in development and disease: new paradigms.

Authors:  Beth L Roman; Andrew P Hinck
Journal:  Cell Mol Life Sci       Date:  2017-09-04       Impact factor: 9.261

9.  A heterodimer formed by bone morphogenetic protein 9 (BMP9) and BMP10 provides most BMP biological activity in plasma.

Authors:  Emmanuelle Tillet; Marie Ouarné; Agnès Desroches-Castan; Christine Mallet; Mariela Subileau; Robin Didier; Anna Lioutsko; Guillaume Belthier; Jean-Jacques Feige; Sabine Bailly
Journal:  J Biol Chem       Date:  2018-05-22       Impact factor: 5.157

10.  GATA2 is required for lymphatic vessel valve development and maintenance.

Authors:  Jan Kazenwadel; Kelly L Betterman; Chan-Eng Chong; Philippa H Stokes; Young K Lee; Genevieve A Secker; Yan Agalarov; Cansaran Saygili Demir; David M Lawrence; Drew L Sutton; Sebastien P Tabruyn; Naoyuki Miura; Marjo Salminen; Tatiana V Petrova; Jacqueline M Matthews; Christopher N Hahn; Hamish S Scott; Natasha L Harvey
Journal:  J Clin Invest       Date:  2015-07-27       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.